About Pharmacyclics (NASDAQ:PCYC)
Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity1.93%
Return on Assets1.52%
Pharmacyclics (NASDAQ:PCYC) Frequently Asked Questions
What is Pharmacyclics' stock symbol?
Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."
How were Pharmacyclics' earnings last quarter?
Pharmacyclics, Inc. (NASDAQ:PCYC) posted its quarterly earnings results on Friday, May, 1st. The biopharmaceutical company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analyst estimates of $226.27 million. Pharmacyclics had a net margin of 2.02% and a return on equity of 1.93%. View Pharmacyclics' Earnings History.
Who are some of Pharmacyclics' key competitors?
Some companies that are related to Pharmacyclics include Iqvia (IQV), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Qiagen (QGEN), Sage Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Icon (ICLR), Covance (CVD), United Therapeutics (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Bio-Techne (TECH), Anacor Pharmaceuticals (ANAC) and Galapagos (GLPG).
How do I buy Pharmacyclics stock?
Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Pharmacyclics?
Pharmacyclics' mailing address is 995 E ARQUES AVE, SUNNYVALE, CA 94085-4521, United States. The biopharmaceutical company can be reached via phone at +1-408-7740330.
MarketBeat Community Rating for Pharmacyclics (PCYC)MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pharmacyclics (NASDAQ:PCYC) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Pharmacyclics (NASDAQ:PCYC) Earnings History and Estimates Chart
Pharmacyclics (NASDAQ PCYC) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2015||Q115||$0.11||$0.13||$226.27 million||$206.00 million||View||N/A|
|2/18/2015||Q414||$0.76||$0.96||$267.50 million||$290.00 million||View||N/A|
|11/4/2014||Q314||$0.37||$0.69||$201.50 million||$207.10 million||View||N/A|
|7/31/2014||Q214||($0.23)||($0.26)||$95.88 million||$113.00 million||View||N/A|
|5/2/2014||Q114||$0.17||$0.40||$105.38 million||$119.40 million||View||N/A|
|2/20/2014||Q413||$0.67||$0.95||$85.69 million||$123.60 million||View||N/A|
|7/31/2013||Q2 2013||($0.07)||$0.26||$52.00 million||$54.70 million||View||N/A|
|5/1/2013||Q3 2013||($0.03)||($0.40)||$2.84 million||View||N/A|
|2/14/2013||Q2 2013||$0.29||$0.62||$45.74 million||$57.96 million||View||N/A|
|11/5/2012||Q113||$0.75||$1.14||$87.64 million||$102.70 million||View||N/A|
|9/5/2012||Q412||($0.27)||($0.22)||$3.49 million||$2.10 million||View||N/A|
Pharmacyclics (NASDAQ:PCYC) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by MarketBeat.com
Pharmacyclics (NASDAQ PCYC) Insider Trading and Institutional Ownership History
Pharmacyclics (NASDAQ PCYC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/13/2015||Manmeet Singh Soni||CFO||Sell||27,514||$254.24||$6,995,159.36|| |
|3/12/2015||Heow Tan||Insider||Sell||1,000||$254.51||$254,510.00|| |
|11/12/2014||Maky Zanganeh||COO||Sell||30,482||$134.69||$4,105,620.58|| |
|11/10/2014||Maky Zanganeh||COO||Sell||23,000||$133.83||$3,078,090.00|| |
|11/10/2014||Richard B Love||General Counsel||Sell||1,500||$133.87||$200,805.00|| |
|11/7/2014||Maky Zanganeh||COO||Sell||1,551||$135.01||$209,400.51|| |
|11/7/2014||Maria Fardis||Insider||Sell||5,000||$134.50||$672,500.00|| |
|9/4/2014||Maky Zanganeh||COO||Sell||12,000||$121.75||$1,461,000.00|| |
|8/27/2014||Richard B Love||General Counsel||Sell||1,500||$124.00||$186,000.00|| |
|8/13/2014||Heow Tan||Insider||Sell||10,000||$123.58||$1,235,800.00|| |
|8/7/2014||Jesse Mcgreivy||Insider||Sell||34,062||$120.92||$4,118,777.04|| |
|3/5/2014||Boultbee Paula Sjovall||EVP||Sell||20,000||$138.22||$2,764,400.00|| |
|3/5/2014||Gregory Hemmi||VP||Sell||15,000||$140.00||$2,100,000.00|| |
|3/5/2014||Jesse Mcgreivy||Insider||Sell||6,563||$139.66||$916,588.58|| |
|3/4/2014||Betty Chang||VP||Sell||17,500||$137.97||$2,414,475.00|| |
|2/27/2014||Den Broek Richard Van||Director||Sell||78,835||$146.63||$11,559,576.05|| |
|12/19/2013||Heow Tan||Insider||Sell||5,000||$100.87||$504,350.00|| |
|12/18/2013||Gregory Hemmi||VP||Sell||20,000||$100.52||$2,010,400.00|| |
|12/16/2013||Rainer Erdtmann||VP||Sell||54,000||$107.77||$5,819,580.00|| |
|6/6/2013||Scott T Shearer||VP||Sell||18,750||$85.17||$1,596,937.50|| |
|5/31/2013||Heow Tan||Insider||Sell||5,237||$91.84||$480,966.08|| |
|5/31/2013||Jesse Mcgreivy||VP||Sell||14,479||$91.13||$1,319,471.27|| |
|2/5/2013||David J Loury||Insider||Sell||20,000||$70.58||$1,411,600.00|| |
|12/28/2012||Den Broek Richard Van||Director||Sell||30,285||$57.99||$1,756,227.15|| |
|12/27/2012||Gregory Hemmi||VP||Sell||13,000||$59.20||$769,600.00|| |
Pharmacyclics (NASDAQ PCYC) News Headlines
Pharmacyclics (NASDAQ:PCYC) SEC Filings
Pharmacyclics (NASDAQ:PCYC) Income Statement, Balance Sheet and Cash Flow Statement
Pharmacyclics (NASDAQ PCYC) Stock Chart for Tuesday, December, 12, 2017